MediSix Therapeutics

MediSix Therapeutics

MediSix is taking a novel approach to engineer chimeric antigen receptor (“CAR”) T-cells to target T-cell leukemia and lymphomas. Their proprietary technology will enable the development of breakthrough treatments for T-cell blood cancers, an area where effective immunotherapies are currently lacking.

<< Portfolio